menu
    • menu

    Company profile for Pulmatrix

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At Pulmatrix, we are developing innovative inhaled therapies to address serious pulmonary disease using our clinically validated, proprietary iSPERSE technology. Leveraging the unique capabilities of iSPERSE to dramatically advance inhalation technology, we can create new therapies to improve patient outcomes. Our pipeline of inhaled therapies rrepresents innovative, first-in-class products. Our proprietary pipeline of novel, ...
    At Pulmatrix, we are developing innovative inhaled therapies to address serious pulmonary disease using our clinically validated, proprietary iSPERSE technology. Leveraging the unique capabilities of iSPERSE to dramatically advance inhalation technology, we can create new therapies to improve patient outcomes. Our pipeline of inhaled therapies rrepresents innovative, first-in-class products. Our proprietary pipeline of novel, therapies for respiratory diseases is led by PUR1900, PUR1800 and PUR5700. PUR1900 is an inhaled anti-infective to treat ABPA in severe asthmatics and cystic fibrosis patients.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    PulmatrixUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    99 Hayden Avenue | Suite 390 Lexington, MA 02421
    Telephone
    Telephone
    781-357-2333
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.pulmatrix.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/pulmatrix-inc.
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/pulmatrix_inc?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pulmatrix Reveals Q3 2025 Financials, Plans To Divest Assets
    Pulmatrix Reveals Q3 2025 Financials, Plans To Divest Assets

    16 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pulmatrix-announces-third-quarter-2025-financial-results-and-divestment-plan-for-migraine-and-inhalation-assets-302585702.html

    PR NEWSWIRE
    16 Oct 2025
    Share Share
    Pulmatrix Unveils Q2 2025 Financials, Plans to Divest Inhalation
    Pulmatrix Unveils Q2 2025 Financials, Plans to Divest Inhalation

    07 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pulmatrix-announces-second-quarter-2025-financial-results-and-divestment-plan-for-inhalation-assets-302522900.html

    PR NEWSWIRE
    07 Aug 2025
    Share Share
    Pulmatrix Announces Q1 2025 Results and Asset Divestment
    Pulmatrix Announces Q1 2025 Results and Asset Divestment

    15 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pulmatrix-announces-first-quarter-2025-financial-results-and-divestment-plan-for-assets-302456356.html

    PR NEWSWIRE
    15 May 2025
    Share Share
    Pulmatrix Announces Q4 2024 Financial Results and Divestment Plan
    Pulmatrix Announces Q4 2024 Financial Results and Divestment Plan

    21 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pulmatrix-announces-year-end-and-fourth-quarter-2024-financial-results-and-divestment-plan-for-assets-302407628.html

    PR NEWSWIRE
    21 Mar 2025
    Share Share
    Pulmatrix & Cullgen Announce Proposed Merger
    Pulmatrix & Cullgen Announce Proposed Merger

    13 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pulmatrix-and-cullgen-announce-proposed-merger-302303818.html

    PR NEWSWIRE
    13 Nov 2024
    Share Share
    Pulmatrix Announces Q3 2024 Financial Results & Corporate Update
    Pulmatrix Announces Q3 2024 Financial Results & Corporate Update

    08 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pulmatrix-announces-third-quarter-2024-financial-results-and-provides-corporate-update-302300066.html

    PR NEWSWIRE
    08 Nov 2024
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search